SCHEMBL23934213

SCHEMBL23934213

O=C(Nc1cc(NC(=O)c2ccccc2)c2c(c1)C(=O)NC2=O)c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 3/20 0.61
RXFP1 Q9HBX9 1/20 0.53
KMT2A Q03164 7/20 0.52
MEN1 O00255 4/20 0.52
ACE2 Q9BYF1 1/20 0.50
KDM4E B2RXH2 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KCNK3 O14649 2/20 0.47
KCNK9 Q9NPC2 2/20 0.47
POLB P06746 2/20 0.47
HTT P42858 1/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
CTDSP1 Q9GZU7 2/20 0.47
MAPT P10636 1/20 0.47
CA12 O43570 1/20 0.47
CA2 P00918 1/20 0.47
CA9 Q16790 1/20 0.47
BRAF P15056 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23934221 0.85 CASP3 (0.60) CASP3RXFP1KMT2AMEN1ACE2
SCHEMBL6264128 0.80 CASP3 (0.86) CASP3RXFP1KMT2AMEN1ACE2
SCHEMBL27099903 0.79 MEN1 (0.54) CASP3KMT2AMEN1ACE2KCNK3
SCHEMBL23934269 0.79 POLB (0.55) CASP3RXFP1KMT2AMEN1KDM4E
SCHEMBL23934281 0.78 MEN1 (0.53) CASP3KMT2AMEN1ACE2KDM4E
SCHEMBL12857981 0.76 CASP3 (1.00) CASP3RXFP1KMT2AMEN1ACE2
SCHEMBL12857823 0.76 CASP3 (1.00) CASP3RXFP1KMT2AMEN1ACE2
SCHEMBL23934210 0.74 KMT2A (0.51) CASP3RXFP1KMT2AMEN1KDM4E
SCHEMBL23923273 0.74 RXFP1 (0.55) CASP3RXFP1KMT2AMEN1KDM4E
SCHEMBL18171018 0.73 CASP3 (0.59) CASP3RXFP1KMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics XAVIER UNIVERSITY OF LOUISIANA (US) 2024-02-27 US disclosed
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS XAVIER UNIVERSITY OF LOUISIANA 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323919-A1 S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS RPS6KA6, RPS6KA1, RPS6KA3 CASP3 3051/4885RXFP1 2817/4885KMT2A 2003/4885
US-11912660-B2 S6K1 protein kinase inhibitors as cancer therapeutics RPS6KA6, RPS6KA1, RPS6KA3 CASP3 3051/4885RXFP1 2817/4885KMT2A 2003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.